IDH2 and leukemia: Using a candidate gene approach, five mutated genes including ASXL1, SRSF2, EZH2, IDH1, and IDH2, which are reported to occur in 25–30% of all PMF patients, were associated with shorter OS and leukemia-free survival (LFS), defining a high-molecular risk (HMR) category [28].